Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 AUD | -4.88% | 0.00% | +77.27% |
Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Dec. 08 | Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.18M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.3M | Net income 2023 | -2M -1.3M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 717K | Net cash position 2023 | 401K 261K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.35% |
1 day | -4.88% | ||
Current month | +56.00% | ||
1 month | +56.00% | ||
3 months | +77.27% | ||
6 months | +34.48% | ||
Current year | +77.27% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.039 | -4.88% | 128 557 |
24-03-27 | 0.041 | -4.65% | 316,429 |
24-03-26 | 0.043 | +10.26% | 361,538 |
24-03-25 | 0.039 | 0.00% | 115,333 |
24-03-21 | 0.039 | +11.43% | 276,473 |
Delayed Quote Australian S.E., March 28, 2024 at 12:46 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+77.27% | 4.49M | |
+9.16% | 45.97B | |
+54.03% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |